Captor Therapeutics S.A. (CTX) - Total Liabilities
Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has total liabilities worth zł11.27 Million PLN (≈ $3.10 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CTX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Captor Therapeutics S.A. - Total Liabilities Trend (2017–2024)
This chart illustrates how Captor Therapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Captor Therapeutics S.A. (CTX) total assets.
Captor Therapeutics S.A. Competitors by Total Liabilities
The table below lists competitors of Captor Therapeutics S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samwha Electri
KO:009470
|
Korea | ₩56.67 Billion |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
Finland | €413.00 Million |
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
India | Rs416.70 Million |
|
AURRIGO INT.PLCLS-002
F:CI0
|
Germany | €5.88 Million |
|
Amulaire Thermal Technology
TW:2241
|
Taiwan | NT$856.52 Million |
|
Kyung Nong Corporation
KO:002100
|
Korea | ₩232.43 Billion |
|
Sat Industries Limited
NSE:SATINDLTD
|
India | Rs1.52 Billion |
|
China Reform Culture Holdings Co Ltd
SHG:600636
|
China | CN¥111.36 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Captor Therapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CTX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Captor Therapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Captor Therapeutics S.A. (2017–2024)
The table below shows the annual total liabilities of Captor Therapeutics S.A. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł23.02 Million ≈ $6.34 Million |
-17.99% |
| 2023-12-31 | zł28.07 Million ≈ $7.73 Million |
+68.33% |
| 2022-12-31 | zł16.68 Million ≈ $4.59 Million |
-13.76% |
| 2021-12-31 | zł19.34 Million ≈ $5.32 Million |
-27.79% |
| 2020-12-31 | zł26.78 Million ≈ $7.37 Million |
+27.42% |
| 2019-12-31 | zł21.02 Million ≈ $5.79 Million |
+43.68% |
| 2018-12-31 | zł14.63 Million ≈ $4.03 Million |
+193.78% |
| 2017-12-31 | zł4.98 Million ≈ $1.37 Million |
-- |
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more